An FDA optometry roundup discusses changes in drug approvals and devices used by optometric eye care professionals.

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

(NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to redefining the retina experience, outlined exceptional clinical progress ... adequate and well-controlled trials to ...